Lite Strategy Inc (LITS) Stock Price, Quote & News

Company Profile

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 858 369 7100

Website: www.litestrategy.com

Address:

9920 Pacific Heights Blvd., Suite 150, San Diego, United States

R3JS Aug. 24 at 4:08 PM

$LTC.X $LITS lits breaks here it’s game on

0 · Reply

gerbens Aug. 24 at 2:27 PM

$LITS huge discount to nav, expect more share buybacks at this price

0 · Reply

R3JS Aug. 23 at 11:51 PM

$LTC.X $LITS channel is painting the bottom for far too long for $LITS

0 · Reply

R3JS Aug. 23 at 2:34 PM

$LTC.X if you are mad you missed $39 guess what you can still buy at $39 it’s called $LITS and it equates out to exactly $39 and they are driven to only equal the exact price of Litecoin at all times. I’m sure it will be up Monday but kinda crazy you can still buy at $39 or close.

0 · Reply

R3JS Aug. 23 at 6:11 AM

$LTC.X $LITS if lits gets to $5.82 you get a yearly buy signal. Let’s just say this I have been trading and following these signals since 2019 and I have never once been a part of a yearly buy signal!!! 🤯🤯🤯

1 · Reply

R3JS Aug. 23 at 6:00 AM

$LITS $LTC.X I just noticed there is a quarterly buy signal on Lits 🤯 ya I said it quarterly!!!!also look how that volume bar hit in 2025 set up the play and the plan of where litecoin is going. If this signal holds it will likely quickly hit that $160 resistance the from there I don’t if it pulls back or break through.

0 · Reply

R3JS Aug. 23 at 12:04 AM

$LTC.X $LITS $MSTR and other strategy stocks will be in the SP 500 in the coming years to support the stock market and has to be done to prevent Elizabeth Warren from being right and completely negates her argument of why to slow down crypto.

0 · Reply

R3JS Aug. 21 at 5:30 PM

$LTC.X $LITS lits market cap just in LTC should be $42M and its $34M basicky buying LTC at a 25% discount plus it goes way higher when it flies

0 · Reply

R3JS Aug. 21 at 4:05 PM

$LTC.X had to switch half my money over to $LITS sorry it was too big of a discount in comparison

1 · Reply

grtttttteasd Aug. 21 at 3:27 PM

$LITS will go parabolic once crypto starts to confirm a reversal

0 · Reply

Lite Strategy Repurchases 13% of Outstanding Shares Since December, Increasing Litecoin Backing Per Share

Jul 25, 2026, 9:00 AM EDT - 4 weeks ago

Lite Strategy Slides: Investor presentation

Jun 19, 2026, 8:30 AM EDT - 2 months ago

Lite Strategy to Attend Panel at Litecoin Foundation Summit in Amsterdam

LTC

2026-06-18T12:48:16.000Z - 2 months ago

Lite Strategy leads strategic investment in LitVM

Jun 18, 2026, 8:30 AM EDT - 2 months ago

Lite Strategy Leads Strategic Investment in LitVM

May 13, 2026, 8:30 AM EDT - 3 months ago

Lite Strategy Reports Fiscal 2026 Third Quarter Results

May 13, 2026, 7:00 AM EDT - 3 months ago

Lite Strategy Quarterly report: Q3 2026

May 13, 2026, 7:00 AM EDT - 3 months ago

Lite Strategy Earnings release: Q3 2026

2026-02-17T14:40:22.000Z - 6 months ago

Lite Strategy reports Q2 EPS (82c) vs. (40c) last year

2026-02-17T14:00:57.000Z - 6 months ago

Lite Strategy to continue to evaluate strategic investments in 2H of 2026

Feb 17, 2026, 8:50 AM EST - 6 months ago

Lite Strategy Reports Fiscal 2026 Second Quarter Results

Feb 17, 2026, 7:00 AM EST - 6 months ago

Lite Strategy Earnings release: Q2 2026

Feb 17, 2026, 7:00 AM EST - 6 months ago

Lite Strategy Quarterly report: Q2 2026

Jan 27, 2026, 7:00 AM EST - 7 months ago

Lite Strategy Proxy statement: Proxy Filing

Dec 30, 2025, 7:00 AM EST - 8 months ago

Lite Strategy Proxy statement: Proxy Filing

Dec 30, 2025, 7:00 AM EST - 8 months ago

Lite Strategy Proxy statement: Proxy Filing

2025-11-19T16:15:44.000Z - 9 months ago

Lite Strategy names acting CEO Justin File to role on a permanent basis

2025-11-17T14:05:45.000Z - 10 months ago

Lite Strategy reports Q1 results, highlights launch of $100M Litecoin Treasury

Nov 14, 2025, 4:00 PM EST - 10 months ago

Lite Strategy Quarterly report: Q1 2026

2025-10-29T13:12:45.000Z - 10 months ago

Lite Strategy announces $25M share repurchase program

2025-10-08T20:50:10.000Z - 11 months ago

Lite Strategy files to sell 780,497 shares of common stock for holders

Oct 8, 2025, 8:00 AM EDT - 11 months ago

Lite Strategy Registration statement: Registration Filing

Sep 26, 2025, 7:00 AM EDT - 11 months ago

Lite Strategy Annual report: Q4 2025

Sep 10, 2025, 9:00 AM EDT - 1 year ago

MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS'

Aug 26, 2025, 8:00 AM EDT - 1 year ago

Lite Strategy Registration statement: Registration Filing

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Lite Strategy Registration statement: Registration Filing

Aug 5, 2025, 8:00 AM EDT - 1 year ago

MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising

Jul 24, 2025, 8:00 PM EDT - 1 year ago

BTC digital asset field continues to exert its strength, HASHJ launches Bitcoin cloud mining platform with "capital + technology" dual-driven mode

Jul 22, 2025, 4:35 PM EDT - 1 year ago

MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange

Jul 18, 2025, 8:30 AM EDT - 1 year ago

MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange

May 13, 2025, 4:05 PM EDT - 1 year ago

MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position

May 13, 2025, 4:00 PM EDT - 1 year ago

Lite Strategy Earnings release: Q3 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Lite Strategy Quarterly report: Q3 2025

Feb 12, 2025, 4:12 PM EST - 1 year ago

MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position

Feb 12, 2025, 12:00 AM EST - 1 year ago

Lite Strategy Earnings release: Q2 2025

Feb 12, 2025, 12:00 AM EST - 1 year ago

Lite Strategy Quarterly report: Q2 2025

Dec 20, 2024, 7:00 AM EST - 1 year ago

Lite Strategy Proxy statement: Proxy Filing

Dec 20, 2024, 7:00 AM EST - 1 year ago

Lite Strategy Proxy statement: Proxy Filing

Nov 12, 2024, 4:05 PM EST - 1 year ago

MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

Nov 12, 2024, 4:00 PM EST - 1 year ago

Lite Strategy Earnings release: Q1 2025

Nov 12, 2024, 4:00 PM EST - 1 year ago

Lite Strategy Quarterly report: Q1 2025

Sep 19, 2024, 4:01 PM EDT - 2 years ago

MEI Pharma Reports Fiscal Year End 2024 Cash Position

Sep 18, 2024, 6:00 PM EDT - 2 years ago

Lite Strategy Earnings release: Q4 2024

Sep 18, 2024, 6:00 PM EDT - 2 years ago

Lite Strategy Annual report: Q4 2024

Aug 12, 2024, 8:30 AM EDT - 2 years ago

MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives

Jul 22, 2024, 8:30 AM EDT - 2 years ago

MEI Pharma to Consider Strategic Alternatives

May 9, 2024, 4:02 PM EDT - 2 years ago

MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights

May 9, 2024, 4:00 PM EDT - 2 years ago

Lite Strategy Quarterly report: Q3 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Lite Strategy Earnings release: Q3 2024

Apr 16, 2024, 1:30 PM EDT - 2 years ago

Lite Strategy Transcript: Stifel Virtual Targeted Oncology Days Conference

Apr 11, 2024, 8:02 AM EDT - 2 years ago

MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344

Apr 11, 2024, 8:00 AM EDT - 2 years ago

MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

Apr 10, 2024, 8:00 AM EDT - 2 years ago

MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum

$MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia$

Mar 26, 2024, 8:00 AM EDT - 2 years ago

MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

Feb 20, 2024, 7:00 AM EST - 2 years ago

Lite Strategy Registration statement: Registration Filing

Feb 13, 2024, 5:05 PM EST - 2 years ago

MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights

Feb 13, 2024, 4:00 PM EST - 2 years ago

Lite Strategy Quarterly report: Q2 2024

Feb 13, 2024, 4:00 PM EST - 2 years ago

Lite Strategy Earnings release: Q2 2024

Jan 16, 2024, 5:00 PM EST - 2 years ago

MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024

Dec 11, 2023, 12:00 PM EST - 2 years ago

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023

Nov 15, 2023, 8:35 AM EST - 3 years ago

Lite Strategy Transcript: The Stifel 2023 Annual Healthcare Conference

Nov 9, 2023, 4:05 PM EST - 3 years ago

MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights

Nov 9, 2023, 4:00 PM EST - 3 years ago

Lite Strategy Quarterly report: Q1 2024

Nov 9, 2023, 4:00 PM EST - 3 years ago

Lite Strategy Earnings release: Q1 2024

Nov 8, 2023, 8:00 AM EST - 3 years ago

MEI Pharma to Present at the Stifel 2023 Healthcare Conference

Nov 8, 2023, 7:00 AM EST - 3 years ago

Lite Strategy Proxy statement: Proxy Filing

Nov 8, 2023, 7:00 AM EST - 3 years ago

Lite Strategy Proxy statement: Proxy Filing

Nov 6, 2023, 4:57 PM EST - 3 years ago

MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock

Nov 2, 2023, 9:00 AM EDT - 3 years ago

MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023

Nov 1, 2023, 9:00 AM EDT - 3 years ago

MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital

Nov 1, 2023, 8:00 AM EDT - 3 years ago

Lite Strategy Proxy statement: Proxy Filing

Oct 18, 2023, 8:00 AM EDT - 3 years ago

Lite Strategy Proxy statement: Proxy Filing

Oct 17, 2023, 5:33 PM EDT - 3 years ago

MEI Pharma Recommends Stockholders Not to Consent

Oct 17, 2023, 8:00 AM EDT - 3 years ago

Lite Strategy Proxy statement: Proxy Filing

Oct 12, 2023, 8:00 AM EDT - 3 years ago

Lite Strategy Proxy statement: Proxy Filing

Oct 10, 2023, 8:00 AM EDT - 3 years ago

Lite Strategy Proxy statement: Proxy Filing

Oct 2, 2023, 8:00 AM EDT - 3 years ago

Lite Strategy Proxy statement: Proxy Filing

Oct 2, 2023, 6:00 AM EDT - 3 years ago

MEI Pharma Adopts Limited-Duration Stockholder Rights Plan

Sep 29, 2023, 8:00 AM EDT - 3 years ago

Lite Strategy Proxy statement: Proxy Filing

Sep 28, 2023, 5:00 PM EDT - 3 years ago

MEI Pharma Issues Statement Regarding Anson and Cable Car's Opportunistic Actions

Sep 28, 2023, 8:00 AM EDT - 3 years ago

Lite Strategy Proxy statement: Proxy Filing

Sep 28, 2023, 8:00 AM EDT - 3 years ago

Lite Strategy Proxy statement: Proxy Filing

Sep 26, 2023, 5:00 PM EDT - 3 years ago

Lite Strategy Earnings Call Transcript: Q4 2023

Sep 26, 2023, 5:00 PM EDT - 3 years ago

Lite Strategy Annual report: Q4 2023

Sep 26, 2023, 5:00 PM EDT - 3 years ago

Lite Strategy Earnings release: Q4 2023

Sep 26, 2023, 4:02 PM EDT - 3 years ago

MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights

Sep 26, 2023, 8:00 AM EDT - 3 years ago

Lite Strategy Proxy statement: Proxy Filing

Sep 21, 2023, 8:00 AM EDT - 3 years ago

MEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023

Sep 18, 2023, 8:00 AM EDT - 3 years ago

MEI Pharma Confirms Receipt of Director Nominations From Anson and Cable Car

Sep 18, 2023, 8:00 AM EDT - 3 years ago

Lite Strategy Proxy statement: Proxy Filing

Sep 15, 2023, 8:00 AM EDT - 3 years ago

Lite Strategy Proxy statement: Proxy Filing

Aug 16, 2023, 8:00 AM EDT - 3 years ago

MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer

Jul 23, 2023, 2:30 PM EDT - 3 years ago

MEI Pharma Announces Results of Special Meeting of Stockholders

Jul 19, 2023, 8:00 AM EDT - 3 years ago

MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction

Jul 18, 2023, 9:00 AM EDT - 3 years ago

MEI Pharma Responds to Anson and Cable Car

Jul 17, 2023, 8:00 AM EDT - 3 years ago

MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction

Jul 17, 2023, 8:00 AM EDT - 3 years ago

Lite Strategy Proxy statement: Proxy Filing

Jul 13, 2023, 4:05 PM EDT - 3 years ago

MEI Pharma Postpones Special Meeting of Shareholders

Jul 11, 2023, 8:00 AM EDT - 3 years ago

MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals

Jul 7, 2023, 8:00 AM EDT - 3 years ago

MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals

Jul 5, 2023, 8:30 AM EDT - 3 years ago

ISS Recommends Infinity Pharmaceuticals Stockholders Vote FOR the Merger with MEI Pharma, Inc.

Jul 5, 2023, 8:00 AM EDT - 3 years ago

MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote “FOR” Pending Transaction with Infinity Pharmaceuticals

Jun 29, 2023, 8:00 AM EDT - 3 years ago

MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals

Jun 15, 2023, 12:08 PM EDT - 3 years ago

MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates

Jun 14, 2023, 7:01 PM EDT - 3 years ago

INFINITY PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Infinity Pharmaceuticals, Inc. - INFI

Jun 13, 2023, 8:00 AM EDT - 3 years ago

MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor

R3JS Aug. 24 at 4:08 PM

$LTC.X $LITS lits breaks here it’s game on

0 · Reply

gerbens Aug. 24 at 2:27 PM

$LITS huge discount to nav, expect more share buybacks at this price

0 · Reply

R3JS Aug. 23 at 11:51 PM

$LTC.X $LITS channel is painting the bottom for far too long for $LITS

0 · Reply

R3JS Aug. 23 at 2:34 PM

0 · Reply

R3JS Aug. 23 at 6:11 AM

1 · Reply

R3JS Aug. 23 at 6:00 AM

0 · Reply

R3JS Aug. 23 at 12:04 AM

0 · Reply

R3JS Aug. 21 at 5:30 PM

$LTC.X $LITS lits market cap just in LTC should be $42M and its $34M basicky buying LTC at a 25% discount plus it goes way higher when it flies

0 · Reply

R3JS Aug. 21 at 4:05 PM

$LTC.X had to switch half my money over to $LITS sorry it was too big of a discount in comparison

1 · Reply

grtttttteasd Aug. 21 at 3:27 PM

$LITS will go parabolic once crypto starts to confirm a reversal

0 · Reply

R3JS Aug. 21 at 3:24 PM

$LITS $LTC.X lits is at a massive discount right now they will match back up today at some point easy free money

0 · Reply

R3JS Aug. 21 at 3:02 PM

$LTC.X this is some stout level 2 buy orders on $LITS

0 · Reply

TheeVoid Aug. 21 at 12:57 PM

$LITS 🔄 4.9M shares bought back…

0 · Reply

R3JS Aug. 20 at 10:51 PM

$LTC.X $LITS $LTCN $LTCC all of them will have a weekly buy if we can close tomorrow at these levels!!! $1 bigher would seal the deal!!

0 · Reply

R3JS Aug. 20 at 8:55 PM

$LITS $LTC.X This company is worth exactly what it’s Litecoin holdings are worth! Market cap $32M Litecoin holdings $32 and how many shares 32M. They are setting this up to take down $MSTR wheb it flies!!

0 · Reply

gerbens Aug. 20 at 3:18 PM

$LITS hopping in for the $1 breakout

0 · Reply

R3JS Aug. 19 at 4:38 PM

$LTC.X $LITS lits is about to get a daily buy signal if this goes a hair higher and holds by close!!

0 · Reply

I_HODL_GOLD Aug. 11 at 12:29 PM

$LITS $LTC.X 13% discount and still to damn high to buy

1 · Reply

Statistical Aug. 10 at 3:37 PM

$LITS RS or delisting coming this year.

0 · Reply

rac0258 Aug. 8 at 2:38 PM

$LITS Balancing the shares and coins owned overall means if they sell coins, they buy back shares. Either way getting more under a dollar, because they may use profits generated q2 to buy more shares.

0 · Reply

WallStRobber Aug. 8 at 1:48 AM

$LITS when delist?

1 · Reply

Statistical Aug. 7 at 9:22 PM

$LITS this crashing tells me $LTC.X has another leg down.

0 · Reply

Market Cap	33.68M
Revenue (ttm)	0.00
Net Income (ttm)	-15.95M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	227,661
Avg Vol	219,456
Day's Range	N/A - N/A
Shares Out	34.03M
Stochastic %K	70%
Beta	0.21
Analysts	Hold
Price Target	N/A